Program
atigotatug
Also written as “BMS-986012” and “BMS-986012 (anti-fucosyl-GM1)”.
Its studies are mostly in Small Cell Lung Carcinoma, led by Bristol-Myers Squibb.
Furthest: phase 2, since Sep 19, 20143 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 30 open or running | phase 2since Sep 19, 2014 | Sep 19, 2014 | none ahead |
- Named in Bristol-Myers Squibb’s own pipeline as
atigotatug
, phase 3, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 19, 2014First study: phase 2 study in Small Cell Lung CarcinomaFirst studyNCT02247349 · 106 enrolled · United States, Australia, Belgium and more
- Jun 24, 2016Phase 1 study in Small Cell Lung CarcinomaNCT02815592 · 12 enrolled · Spain
- Oct 28, 2016Phase 1 study in Small Cell Lung CarcinomaNCT02949895 · 7 enrolled · Japan
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02949895Small Cell Lung Carcinoma · Japan | 1 | Completed | Aug 29, 2017 | 7 |
| NCT02815592Small Cell Lung Carcinoma · Spain | 1 | Completed | Dec 15, 2019 | 12 |
| NCT02247349Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 2 | Completed | Dec 21, 2022 | 106 |
How it is read
Names in the registry
- “BMS-986012”, 2 entries
- “BMS-986012 (anti-fucosyl-GM1)”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.